文献速递前列腺癌

长链非编码RNA在前列腺癌发生发展中的认可演变及其在疾病管理中的临床效用

The evolution of long noncoding RNA acceptance in prostate cancer initiation, progression, and its clinical utility in disease management.
PubMed 文献 · Eur Urol · 2019-08-22

本文通过系统综述PubMed过去30年(1988-2018)关于长链非编码RNA(lncRNA)与前列腺癌(PCa)的研究,梳理lncRNA在肿瘤风险与起始、促进、抑制及治疗抵抗中的功能机制,并评估其在诊断、预后、预测及治疗靶点方面的临床价值。结论认为lncRNA生物学功能多样,参与PCa各阶段,其诊断预后预测价值获较好支持,但治疗候选资格需进一步评估。

要点

  • lncRNA在PCa风险起始、促进、抑制及治疗抵抗中均发挥功能。
  • lncRNA作为PCa诊断、预后和预测的生物标志物获较好支持。
  • lncRNA作为治疗靶点的潜力需临床试验进一步评估。

核心结论

  • lncRNA生物学功能多样,参与PCa各阶段;其诊断、预后和预测的临床效用获较好支持,但治疗候选资格需进一步评估。

研究设计与样本

  • 系统综述,检索PubMed过去30年(1988-2018)关于长链非编码RNA、前列腺与癌症的文献。

主要发现

  • 按肿瘤风险与起始、肿瘤促进、肿瘤抑制和肿瘤治疗抵抗对lncRNA进行机制分类并描述历史时间线。
  • 综述了在诊断、预后和预测中具有临床效用的lncRNA,并评估其作为治疗靶点的潜力。

临床怎么用

  • 作者认为lncRNA作为PCa诊断、预后和预测的生物标志物获较好支持,但作为治疗靶点需进一步评估。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: It is increasingly evident that non-protein-coding regions of the genome can give rise to transcripts that form functional layers of the cancer genome. One of most abundant classes in these regions is long noncoding RNAs (lncRNAs). They have gained increasing attention in prostate cancer (PCa) and paved the way for a greater understanding of these cryptic regulators in cancer. OBJECTIVE: To review current research exploring the functional biology of lncRNAs in PCa over the past three decades. EVIDENCE ACQUISITION: A systematic review was performed using PubMed to search for reports with terms "long noncoding RNA", "prostate", and "cancer" over the past 30 yr (1988-2018). EVIDENCE SYNTHESIS: We comprehensively surveyed the literature collected and summarise experiments leading to the characterisation of lncRNAs in PCa. A historical timeline of lncRNA identification is described, where each lncRNA is categorised mechanistically and within the primary areas of carcinogenesis: tumour risk and initiation, tumour promotion, tumour suppression, and tumour treatment resistance. We describe select lncRNAs that exemplify these areas. We also review whether these lncRNAs have a clinical utility in PCa diagnosis, prognosis, and prediction, and as therapeutic targets. CONCLUSIONS: The biology of lncRNA is multifaceted, demonstrating a complex array of molecular and cellular functions. These studies reveal that lncRNAs are involved in every stage of PCa. Their clinical utility for diagnosis, prognosis, and prediction of PCa is well supported, but further evaluation for their therapeutic candidacy is needed. We provide a detailed resource and view inside the lncRNA landscape for other cancer biologists, oncologists, and clinicians. PATIENT SUMMARY: In this study, we review current knowledge of the non-protein-coding genome in prostate cancer (PCa). We conclude that many of these regions are functional and a source of accurate biomarkers in PCa. With a strong research foundation, they hold promise as future therapeutic targets, yet clinical trials are necessary to determine their intrinsic value to PCa disease management.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Ramnarine VR, Kobelev M, Gibb EA, et al. The evolution of long noncoding RNA acceptance in prostate cancer initiation, progression, and its clinical utility in disease management. Eur Urol. 2019. PMID: 31445843. doi:10.1016/j.eururo.2019.07.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。